Eddy Rubin has been appointed acting director and acting division director of the genomics division of the Joint Genome Institute at Lawrence Berkeley National Lab, as the JGI searches for a permanent director to replace Trevor Hawkins.
Hawkins has stepped down to become Amersham’s senior vice president for genomics.
Rubin is currently a senior scientist and head of genome sciences at Berkeley labs. His research focuses on biological annotation of mammalian genomes and using expression profiling to identify regulatory gene sequences.
Hawkins is gradually reducing his involvement at JGI as he moves into the Amersham position. His title at JGI is now consulting director. Institute representatives have said that they hope to identify a replacement by the summer.
Pharmacogenomics and diagnostics company Variagenics has appointed Joseph (Jay) Mohr, formerly its vice president of marketing and business development, as its new CEO. Mohr replaces Taylor Crouch, who has resigned. Richard Shea, the company’s chief financial officer, will assume the newly created position of chief operating officer.
Raymond Withy has begun his tenure as CEO at monoclonal antibody company Abgenix, replacing current CEO Scott Greer. Withy, formerly the company’s president and chief operating officer, has also served as chief business officer and vice president of corporate development at the company, as well as director of business development at Cell Genesys, of which Abgenix is a spin-off. Prior to these positions, Withy also worked in research and development at Genzyme and Integrated Genetics. Withy received his PhD in biochemistry from the University of Nottingham in the UK, and completed a postdoctoral fellowship at Cal Tech.